PIN30 ESTIMATED BUDGET IMPACT OF THE INTRODUCTION OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) IN THE UNITED STATES FOR THE TREATMENT OF HIV INFECTION

Abstract

Authors

A. Oglesby S.J. Anderson Y.S. Punekar

Full Text Cite This Article
Back to Volume 23, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×